Literature DB >> 25608086

Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels.

T Ito1, T Kumada1, H Toyoda1, T Tada1, S Kiriyama1, M Tanikawa1, Y Hisanaga1, A Kanamori1, S Kitabatake1.   

Abstract

The FIB-4 index is a simple formula using age, aspartate aminotransferase, alanine aminotransferase (ALT) and platelet count to evaluate liver fibrosis. We investigated the ability of the FIB-4 index for hepatocarcinogenesis in hepatitis C virus (HCV) carriers with normal ALT levels. A total of 516 patients with ALT levels persistently at or below 40 IU/L during an observation period of over 3 years were included. Factors associated with the development of HCC were determined. Hepatocellular carcinoma (HCC) developed in 60 of 516 patients (11.6%). The incidence rate of HCC at 5 and 10 years was 2.6% and 17.6%, respectively. When patients were categorized according to the FIB-4 index as ≤ 2.0 (n = 226), >2.0 and ≤ 4.0 (n = 169), and > 4.0 (n = 121), the cumulative incidence of HCC at 5 years was 0.5%, 1.3% and 8.0%, respectively, and 2.8%, 25.6% and 37.1% at 10 years, respectively. Patients with FIB-4 index >4.0 were at the highest risk (P < 0.001). Factors that were significantly associated with HCC in the multivariate analysis were FIB-4 index >2.0 (hazard ratio (HR), 7.690), FIB-4 index >4.0 (HR, 8.991), α-fetoprotein (AFP) >5 ng/mL (HR, 2.742), AFP >10 ng/mL (HR, 4.915) and total bilirubin >1.2 mg/dL (HR, 2.142). A scoring system for hepatocarcinogenesis that combines the FIB-4 index and AFP predicted patient outcomes with excellent discriminative ability. The FIB-4 index is strongly associated with the risk of HCC in HCV carriers with normal ALT levels.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  FIB-4 index; hepatitis C; hepatocellular carcinoma; α-fetoprotein

Mesh:

Substances:

Year:  2015        PMID: 25608086     DOI: 10.1111/jvh.12389

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  3 in total

1.  Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C.

Authors:  Mohamed Alboraie; Kerstin Schütte; Marwa Khairy; Marwa Elsharkawy; Noha Asem; Fathy Elghamry; Helmy Shalaby; Gamal Esmat; Peter Malfertheiner
Journal:  Saudi Med J       Date:  2017-11       Impact factor: 1.484

2.  Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Yi-You Chiou; Chien-Wei Su; Yun-Hsuan Lee; Yi-Hsiang Huang; Fa-Yauh Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Sci Rep       Date:  2018-01-16       Impact factor: 4.379

Review 3.  Non-invasive tests for the prediction of primary hepatocellular carcinoma.

Authors:  Giovanni Marasco; Antonio Colecchia; Giovanni Silva; Benedetta Rossini; Leonardo Henry Eusebi; Federico Ravaioli; Elton Dajti; Luigina Vanessa Alemanni; Luigi Colecchia; Matteo Renzulli; Rita Golfieri; Davide Festi
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.